This study presents the development of a replication-competent recombinant VSV-ΔG-spike vaccine, replacing the VSV glycoprotein with the SARS-CoV-2 spike protein. In vitro characterization showed spike protein expression and antigenic similarity to SARS-CoV-2. A single dose in golden Syrian hamsters induced neutralizing antibodies and protected against SARS-CoV-2 challenge, evidenced by reduced weight loss and tissue damage. The vaccine is suggested as a safe and effective option against SARS-CoV-2.